XHKG2367
Market cap6.70bUSD
Dec 23, Last price
51.30HKD
1D
-0.10%
1Q
28.25%
IPO
62.86%
Name
Giant Biogene Holding Co Ltd
Chart & Performance
P/E
33.68
P/S
13.87
EPS
1.43
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3.52b
+49.05%
Net income
1.45b
+44.88%
CFO
1.65b
+76.83%
Dividend
Jun 17, 20240.49 HKD/sh
Profile
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 3,524,143 49.05% | 2,364,445 52.30% | 1,552,486 30.41% | ||
Cost of revenue | 1,913,134 | 1,230,691 | 576,244 | ||
Unusual Expense (Income) | |||||
NOPBT | 1,611,009 | 1,133,754 | 976,242 | ||
NOPBT Margin | 45.71% | 47.95% | 62.88% | ||
Operating Taxes | 296,887 | 176,163 | 144,785 | ||
Tax Rate | 18.43% | 15.54% | 14.83% | ||
NOPAT | 1,314,122 | 957,591 | 831,457 | ||
Net income | 1,451,753 44.88% | 1,002,025 21.00% | 828,132 0.20% | ||
Dividends | (367,460) | (2,550,000) | |||
Dividend yield | 1.07% | ||||
Proceeds from repurchase of equity | 56,398 | (5,652,343) | 57 | ||
BB yield | -0.16% | 16.47% | |||
| Debt | |||||
Debt current | 1,563 | 881 | |||
Long-term debt | 3,895 | 4,291 | |||
Deferred revenue | 19,575 | 18,179 | 17,584 | ||
Other long-term liabilities | |||||
Net debt | (3,773,317) | (2,191,752) | (7,258,607) | ||
| Cash flow | |||||
Cash from operating activities | 1,647,431 | 931,637 | 692,401 | ||
CAPEX | (226,300) | (153,249) | (111,191) | ||
Cash from investing activities | (527,282) | (858,737) | 1,563,266 | ||
Cash from financing activities | 51,808 | (5,789,766) | 4,475,544 | ||
FCF | 2,059,600 | (165,985) | 778,645 | ||
| Balance | |||||
Cash | 3,778,775 | 2,196,924 | 7,258,607 | ||
Long term investments | |||||
Excess cash | 3,602,568 | 2,078,702 | 7,180,983 | ||
Stockholders' equity | 2,492,010 | 1,240,165 | 81 | ||
Invested Capital | 1,901,344 | 1,537,153 | 954,723 | ||
ROIC | 76.44% | 76.86% | 207.84% | ||
ROCE | 36.25% | 40.82% | 102.16% | ||
| EV | |||||
Common stock shares outstanding | 982,717 | 1,021,215 | 991,609 | ||
Price | 35.60 5.95% | 33.60 | |||
Market cap | 34,984,722 1.96% | 34,312,809 | |||
EV | 31,220,315 | 32,124,618 | |||
EBITDA | 1,645,184 | 1,161,382 | 1,000,452 | ||
EV/EBITDA | 18.98 | 27.66 | |||
Interest | 112 | 21 | |||
Interest/NOPBT | 0.01% | 0.00% | |||